Focus on Diabetes Care

Back to articles

Intensive glycemic control did not result in long-term CV benefits

KEY POINT

The New England Journal of Medicine published a 15-year follow-up from the Veterans Affairs Diabetes Trial (VADT), in which patients were randomized to either intensive or standard glucose lowering. This study found no significant difference between the groups for cardiovascular (CV) outcomes or all-cause mortality and suggested that there is no evidence of a legacy effect or mortality benefit with intensive glucose control.

SOURCES

Reaven PD, et al. Intensive glucose control in patients with type 2 diabetes – 15-year follow-up. N Engl J Med. 2019;380(23):2215–24.

Lipska KJ, et al. Lack of glycemic legacy effects in the Veterans Affairs Diabetes Trial. N Engl J Med. 2019;380(23):2266–7.